← Back to Clinical Trials
Recruiting NCT05387551

NCT05387551 CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05387551
Status Recruiting
Phase
Sponsor Nemours Children's Clinic
Condition Impaired Glucose Tolerance
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2022-12-01
Primary Completion 2026-06

Trial Parameters

Condition Impaired Glucose Tolerance
Sponsor Nemours Children's Clinic
Study Type INTERVENTIONAL
Phase N/A
Enrollment 15
Sex ALL
Min Age 10 Years
Max Age 18 Years
Start Date 2022-12-01
Completion 2026-06
Interventions
CGM

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.

Eligibility Criteria

Inclusion Criteria: 1. Children 10 to \<18 years old (i.e., before their 18th birthday) 2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) or fasting glucose per American Diabetes Association criteria, 3. Overweight or obese (BMI ≥85th percentile for age/sex) 4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL Exclusion Criteria: 1. Existing diagnosis of type 1 or type 2 diabetes 2. Prepubertal 3. Taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). Metformin allowed if stable dose. 4. Patients and/or families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology